

## Alimta<sup>®</sup> (pemetrexed disodium) – First-time generic

- On May 27, 2022, <u>Dr. Reddy's</u>, <u>Aurobindo</u>, <u>Apotex</u>, <u>Fresenius Kabi</u>, <u>Zydus</u>, and <u>Accord launched</u> AP-rated generic versions of Eli Lilly's <u>Alimta (pemetrexed disodium)</u> injection.
  - Additional AP-rated generics for Alimta were FDA-approved on May 25, 2022: <u>Hospira</u>, <u>Jiangsu Hansoh</u>, <u>Nang Kuang</u>, <u>Qilu</u>, and <u>Waverly</u>. Launch dates for these generics are pending.
- Alimta is approved for the treatment of non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
- Pemetrexed is also available as a brand intravenous solution (<u>Pemfexy<sup>™</sup></u>) approved for the same indications as Alimta.
- According to IQVIA Health, Alimta had U.S. sales of approximately \$1.2 billion for the 12 months ending in March 2022.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.